title: Wfs1-deficient mice display altered function of serotonergic system and increased behavioral response to antidepressants.
abstract: It has been shown that mutations in the WFS1 gene make humans more susceptible to mood disorders. Besides that, mood disorders are associated with alterations in the activity of serotonergic and noradrenergic systems. Therefore, in this study, the effects of imipramine, an inhibitor of serotonin (5-HT) and noradrenaline (NA) reuptake, and paroxetine, a selective inhibitor of 5-HT reuptake, were studied in tests of behavioral despair. The tail suspension test (TST) and forced swimming test (FST) were performed in Wfs1-deficient mice. Simultaneously, gene expression and monoamine metabolism studies were conducted to evaluate changes in 5-HT- and NA-ergic systems of Wfs1-deficient mice. The basal immobility time of Wfs1-deficient mice in TST and FST did not differ from that of their wild-type littermates. However, a significant reduction of immobility time in response to lower doses of imipramine and paroxetine was observed in homozygous Wfs1-deficient mice, but not in their wild-type littermates. In gene expression studies, the levels of 5-HT transporter (SERT) were significantly reduced in the pons of homozygous animals. Monoamine metabolism was assayed separately in the dorsal and ventral striatum of naive mice and mice exposed for 30 min to brightly lit motility boxes. We found that this aversive challenge caused a significant increase in the levels of 5-HT and 5-hydroxyindoleacetic acid (5-HIAA), a metabolite of 5-HT, in the ventral and dorsal striatum of wild-type mice, but not in their homozygous littermates. Taken together, the blunted 5-HT metabolism and reduced levels of SERT are a likely reason for the elevated sensitivity of these mice to the action of imipramine and paroxetine. These changes in the pharmacological and neurochemical phenotype of Wfs1-deficient mice may help to explain the increased susceptibility of Wolfram syndrome patients to depressive states.
authors.affiliation: Department of Physiology, University of Tartu Tartu, Estonia ; Centre for Excellence in Translational Medicine, University of Tartu Tartu, Estonia.
authors.forename: Tanel
authors.initials: T
authors.lastname: Visnapuu
authors.forename: Sirli
authors.initials: S
authors.lastname: Raud
authors.forename: Maarja
authors.initials: M
authors.lastname: Loomets
authors.forename: Riin
authors.initials: R
authors.lastname: Reimets
authors.forename: Silva
authors.initials: S
authors.lastname: Sütt
authors.forename: Hendrik
authors.initials: H
authors.lastname: Luuk
authors.forename: Mario
authors.initials: M
authors.lastname: Plaas
authors.forename: Sulev
authors.initials: S
authors.lastname: Kõks
authors.forename: Vallo
authors.initials: V
authors.lastname: Volke
authors.forename: Aet
authors.initials: A
authors.lastname: Alttoa
authors.forename: Jaanus
authors.initials: J
authors.lastname: Harro
authors.forename: Eero
authors.initials: E
authors.lastname: Vasar
keywords: Wfs1-deficient mice; behavioral despair; forced swimming test; imipramine; noradrenaline reuptake transporter; paroxetine; serotonin reuptake transporter; tail suspension test
references.citation: Behav Pharmacol. 2009 Feb;20(1):18-32
references.pmid: 19179848
references.citation: J Psychopharmacol. 2010 Jun;24(6):905-13
references.pmid: 19346280
references.citation: Nature. 2008 Oct 16;455(7215):894-902
references.pmid: 18923511
references.citation: Biol Psychiatry. 2001 Apr 1;49(7):575-81
references.pmid: 11297714
references.citation: Biol Psychiatry. 1999 Nov 15;46(10):1375-87
references.pmid: 10578452
references.citation: Hum Mol Genet. 2004 Jun 1;13(11):1159-70
references.pmid: 15056606
references.citation: J Pers Soc Psychol. 1984 Apr;46(4):877-91
references.pmid: 6737198
references.citation: Mol Psychiatry. 1998 Jan;3(1):86-91
references.pmid: 9491819
references.citation: J Pharmacol Exp Ther. 1988 Dec;247(3):1032-8
references.pmid: 2905001
references.citation: Physiol Behav. 2007 Nov 23;92(4):734-40
references.pmid: 17707870
references.citation: Biol Psychiatry. 2006 Jun 15;59(12):1151-9
references.pmid: 16566899
references.citation: Behav Brain Res. 2009 Mar 17;198(2):334-45
references.pmid: 19041897
references.citation: Neuropharmacology. 2009;56 Suppl 1:122-32
references.pmid: 18675281
references.citation: J Comp Neurol. 2008 Aug 20;509(6):642-60
references.pmid: 18551525
references.citation: Psychopharmacology (Berl). 2003 Apr;166(4):373-82
references.pmid: 12601501
references.citation: Pharmacol Biochem Behav. 2001 Oct-Nov;70(2-3):187-92
references.pmid: 11701187
references.citation: J Pharmacol Exp Ther. 1997 Dec;283(3):1305-22
references.pmid: 9400006
references.citation: Biol Psychiatry. 1999 Nov 1;46(9):1275-86
references.pmid: 10560033
references.citation: Behav Brain Res. 2005 Nov 7;164(2):266-9
references.pmid: 16087251
references.citation: Behav Brain Res. 2003 Aug 14;143(2):193-200
references.pmid: 12900045
references.citation: Biol Psychiatry. 1998 Dec 1;44(11):1090-8
references.pmid: 9836013
references.citation: Behav Brain Res. 2013 May 1;244:90-9
references.pmid: 23396150
references.citation: Int J Neuropsychopharmacol. 2005 Jun;8(2):235-44
references.pmid: 15473915
references.citation: Behav Genet. 2007 Jan;37(1):171-213
references.pmid: 17029009
references.citation: Mayo Clin Proc. 2001 May;76(5):511-27
references.pmid: 11357798
references.citation: Neurosci Res. 2008 Jun;61(2):143-58
references.pmid: 18343518
references.citation: Biol Psychiatry. 2000 May 1;47(9):787-93
references.pmid: 10812037
references.citation: Life Sci. 1993;52(12):1023-9
references.pmid: 8445992
references.citation: Arch Int Pharmacodyn Ther. 1977 Oct;229(2):327-36
references.pmid: 596982
references.citation: J Physiol Biochem. 2011 Mar;67(1):53-60
references.pmid: 20972658
references.citation: Mol Psychiatry. 2005 Aug;10(8):799-803
references.pmid: 15852062
references.citation: Lancet. 1990 Sep 15;336(8716):667-9
references.pmid: 1975860
references.citation: Depress Anxiety. 2010 Apr;27(4):339-50
references.pmid: 19960531
references.citation: Soc Sci Med. 1988;26(3):309-17
references.pmid: 3279520
references.citation: Arch Int Pharmacodyn Ther. 1987 Jul;288(1):11-30
references.pmid: 2889430
references.citation: Clin Chem. 2009 Aug;55(8):1578-9
references.pmid: 19498050
references.citation: J Exp Anal Behav. 2012 Jan;97(1):125-46
references.pmid: 22287808
references.citation: J Neurosci. 2007 Aug 1;27(31):8161-5
references.pmid: 17670959
references.citation: Neurosci Lett. 2009 Aug 28;460(2):138-42
references.pmid: 19477223